Hoth Therapeutics Shares Rally on Positive Alzheimer's Pre-clinical Study Data

Dow Jones

Sep 17, 2024

By Michael Susin

Hoth Therapeutics shares rose on Tuesday after the company said early clinical data of its therapeutic HT-ALZ suggested a potential "breakthrough" in the treatment of Alzheimer's disease.

Shares in premarket trading were up nearly 15% to $1.16. On a year-to-date basis, shares are down nearly 30%.

The New York-based biopharmaceutical company said that early observations of a pre-clinical study showed that HT-ALZ treated groups of mice presented notably fewer reactive astrocytes, the drivers of neurodegenerative diseases like Alzheimer's, when compared to the vehicle-treated group.

The company said these reductions corresponded with enhanced cognitive performance, adding that these results pointed to a potential breakthrough in the treatment of Alzheimer's.

Hoth Therapeutics said it plans to continue advancing HT-ALZ through further studies and clinical trials.

Write to Michael Susin at michael.susin@wsj.com

(END) Dow Jones Newswires

September 17, 2024 09:14 ET (13:14 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2468354356"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2468354356\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2468354356?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-09-17 21:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2468354356","market":"hk","top_or_hot":-1,"title":"Hoth Therapeutics Shares Rally on Positive Alzheimer's Pre-clinical Study Data","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Michael Susin \n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/HOTH\">Hoth Therapeutics</a> shares rose on Tuesday after the company said early clinical data of its therapeutic HT-ALZ suggested a potential \"breakthrough\" in the treatment of Alzheimer's disease. \n</p>\n<p>\n  Shares in premarket trading were up nearly 15% to $1.16. On a year-to-date basis, shares are down nearly 30%. \n</p>\n<p>\n  The New York-based biopharmaceutical company said that early observations of a pre-clinical study showed that HT-ALZ treated groups of mice presented notably fewer reactive astrocytes, the drivers of neurodegenerative diseases like Alzheimer's, when compared to the vehicle-treated group. \n</p>\n<p>\n  The company said these reductions corresponded with enhanced cognitive performance, adding that these results pointed to a potential breakthrough in the treatment of Alzheimer's. \n</p>\n<p>\n  Hoth <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> said it plans to continue advancing HT-ALZ through further studies and clinical trials. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Michael Susin at michael.susin@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  September 17, 2024 09:14 ET (13:14 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hoth Therapeutics Shares Rally on Positive Alzheimer's Pre-clinical Study Data</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHoth Therapeutics Shares Rally on Positive Alzheimer's Pre-clinical Study Data\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2024-09-17 21:14</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Michael Susin \n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/HOTH\">Hoth Therapeutics</a> shares rose on Tuesday after the company said early clinical data of its therapeutic HT-ALZ suggested a potential \"breakthrough\" in the treatment of Alzheimer's disease. \n</p>\n<p>\n  Shares in premarket trading were up nearly 15% to $1.16. On a year-to-date basis, shares are down nearly 30%. \n</p>\n<p>\n  The New York-based biopharmaceutical company said that early observations of a pre-clinical study showed that HT-ALZ treated groups of mice presented notably fewer reactive astrocytes, the drivers of neurodegenerative diseases like Alzheimer's, when compared to the vehicle-treated group. \n</p>\n<p>\n  The company said these reductions corresponded with enhanced cognitive performance, adding that these results pointed to a potential breakthrough in the treatment of Alzheimer's. \n</p>\n<p>\n  Hoth <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> said it plans to continue advancing HT-ALZ through further studies and clinical trials. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Michael Susin at michael.susin@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  September 17, 2024 09:14 ET (13:14 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HOTH","symbol_name":"Hoth Therapeutics","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2468354356","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2468354356","pubTimestamp":1726578840,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Hoth Therapeutics shares rose on Tuesday after the company said early clinical data of its therapeutic HT-ALZ suggested a potential \"breakthrough\" in the treatment of Alzheimer's disease.Shares in premarket trading were up nearly 15% to $1.16. On a year-to-date basis, shares are down nearly 30%.The New York-based biopharmaceutical company said that early observations of a pre-clinical study showed that HT-ALZ treated groups of mice presented notably fewer reactive astrocytes, the drivers of neurodegenerative diseases like Alzheimer's, when compared to the vehicle-treated group.The company said these reductions corresponded with enhanced cognitive performance, adding that these results pointed to a potential breakthrough in the treatment of Alzheimer's.Hoth Therapeutics said it plans to continue advancing HT-ALZ through further studies and clinical trials.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HOTH":"Hoth Therapeutics","01611":"新火科技控股","BK1167":"电子制造服务","BK4007":"制药"},"translate_title":"Hoth Therapeutics股价因积极的阿尔茨海默病临床前研究数据而上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HOTH":1,"01611":0.9},"content_text":"By Michael Susin \n\n\n \n\n\nHoth Therapeutics shares rose on Tuesday after the company said early clinical data of its therapeutic HT-ALZ suggested a potential \"breakthrough\" in the treatment of Alzheimer's disease. \n\n\n  Shares in premarket trading were up nearly 15% to $1.16. On a year-to-date basis, shares are down nearly 30%. \n\n\n  The New York-based biopharmaceutical company said that early observations of a pre-clinical study showed that HT-ALZ treated groups of mice presented notably fewer reactive astrocytes, the drivers of neurodegenerative diseases like Alzheimer's, when compared to the vehicle-treated group. \n\n\n  The company said these reductions corresponded with enhanced cognitive performance, adding that these results pointed to a potential breakthrough in the treatment of Alzheimer's. \n\n\n  Hoth Therapeutics said it plans to continue advancing HT-ALZ through further studies and clinical trials. \n\n\n \n\n\n  Write to Michael Susin at michael.susin@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  September 17, 2024 09:14 ET (13:14 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}